Core Viewpoint - WuXi AppTec is positioned as a leading integrated CRDMO provider, delivering efficient services to the global pharmaceutical and life sciences industry through continuous internal and external development [1] Group 1: Company Overview - WuXi AppTec offers integrated, end-to-end new drug research and production services [1] - The management team possesses extensive experience in the pharmaceutical industry and has a global perspective [1] - The company is actively launching H-share incentive trust plans to attract and motivate key talent [1] Group 2: Financial Performance - The integrated CRDMO segment is expected to experience a slight revenue decline in 2024, but the performance in the first half of 2025 is anticipated to be strong [1] - The initial coverage of the company has been rated as "Buy" [1]

Core Insights - The report recommends key stocks across various industries for January 2026, highlighting potential investment opportunities based on market trends and company performance [2][3]. Industry Summaries Construction - Shenghui Integration (603163.SH) is a Taiwanese cleanroom engineering service provider and a core supplier for Google's TPU supply chain, poised to benefit from TSMC's expansion in the U.S. with potential orders from TSMC Arizona and multiple North American data centers [2]. Social Services - China Duty Free Group (601888.SH) is expected to benefit from a new cycle in domestic duty-free sales, with a boost from the upcoming consumption peak during the New Year and Spring Festival, leading to improved performance expectations [2]. Electronics - Lante Optics (688127.SH) is experiencing significant growth in its optical prism product line and is collaborating with multiple waveguide manufacturers for AR glasses, indicating strong profit elasticity and expansion potential [2]. Utilities and Environmental Protection - China General Nuclear Power (003816.SZ) is set to benefit from the normalization of nuclear power approvals and improvements in market pricing mechanisms, with expected production increases in Guangdong province [2]. Nonferrous Metals - Zijin Mining (601899.SH) is a leading player in the nonferrous sector, with high profit contributions from gold and copper, and is entering a rapid growth phase in lithium production, making it a highly valued investment opportunity for 2026 [2]. Agriculture, Forestry, Animal Husbandry, and Fishery - Youran Dairy (9858.HK), a global leader in dairy farming, is expected to benefit from rising milk prices and beef price increases, leading to significant performance recovery [2]. Internet - Tencent Holdings (0700.HK) is well-positioned for the AI era, leveraging its ecosystem advantages, with potential growth from e-commerce and AI agent capabilities not yet reflected in current profit forecasts [2]. Pharmaceuticals - WuXi AppTec (603259.SH) is supported by strong performance, order growth, and capital expenditure, with favorable regulatory changes expected to enhance the valuation of the CXO sector [2]. Light Industry - Sun Paper (002078.SZ) is entering a new capacity release phase with significant production increases expected, making it a compelling investment with reasonable valuation metrics [2]. Textiles and Apparel - Anta Sports (2020.HK) is anticipated to benefit from the performance of its premium sports brands, with a favorable valuation and upcoming catalysts from Q4 operational disclosures and the Spring Festival consumption peak [2].

Core Viewpoint - Major companies in China, including JD.com and ByteDance, are significantly increasing employee salaries and bonuses, reflecting a broader trend aimed at boosting consumer spending and addressing income inequality in the economy [6][7][20]. Group 1: Salary Increases and Bonuses - JD.com announced that 92% of its employees will receive full or exceeding year-end bonuses, with total bonus investment increasing by over 70% year-on-year for 2025 [6][11]. - ByteDance revealed a 35% increase in bonus investment and a 1.5 times increase in salary adjustment investment for 2025, aiming to attract and retain talent [7][12]. - Other major companies like BYD and CATL are also raising salaries, with CATL increasing basic wages for frontline workers by 150 yuan starting January 1, 2026 [16][19]. Group 2: Industry Trends and Economic Context - The central economic work conference emphasized the need for a plan to increase urban and rural residents' income, indicating a shift towards implementing concrete measures rather than just proposals [21][22]. - The increase in salaries by major companies is seen as a direct method to enhance consumer spending power, which is crucial for driving domestic demand [20][23]. - The overall trend of salary increases across various sectors, including technology, manufacturing, and pharmaceuticals, signals a collective effort to improve employee compensation and stimulate economic growth [19][24].

据香港交易所披露，贝莱德（BlackRock）对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例 于2025年12月23日从5.1%降至4.72%。 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report emphasizes the potential of brain-computer interface (BCI) technology and AI medical applications, predicting significant developments in 2026. It suggests focusing on innovative drug stocks and medical technology themes, particularly in the context of an aging population and the recovery of consumer spending in healthcare [3][5][42]. Summary by Sections 1. Policy Catalysts and BCI Application Potential - The brain-computer interface (BCI) technology is highlighted as a key area of growth, with the market expected to reach approximately $2.62 billion by 2024 and grow to $12.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2034 [12][18]. - The medical sector is projected to account for about 46% of the BCI application market in 2024, focusing on areas such as neurological rehabilitation and sensory diagnostics [13][18]. 2. Industry Perspective: Innovation and Global Expansion - The pharmaceutical index has shown a decline of 0.18% from December 22 to December 26, 2025, with a year-to-date increase of 14.29%. The report notes a significant number of stocks experiencing both gains and losses during this period [25][30]. - The report identifies key stocks to watch, including innovative drug companies and those involved in the BCI and AI medical sectors, suggesting a focus on companies like Heng Rui Medicine, Zai Lab, and others [42][45]. 3. Investment Opportunities - The report suggests that the pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs leading the way. It highlights the increasing global competitiveness of Chinese pharmaceutical companies and their growing capabilities in international markets [41][42]. - Specific recommendations include focusing on innovative drugs, medical devices, and companies involved in the BCI sector, with a particular emphasis on those with strong fundamentals and potential for recovery in 2026 [42][44].

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Summary of Key Points from the Equity Research Report Industry Overview - The report focuses on the **China CXO (Contract Research Organization) sector**, highlighting growth prospects and investment opportunities for 2026 and beyond [2][3]. Core Insights and Arguments - The **2026 National Defense Authorization Act (NDAA)** was signed, which includes a revised Biosecure provision that reduces geopolitical risks and ensures continuity of US orders for Chinese companies [3][4]. - The **Federal Reserve's anticipated rate cuts** (two to three 25 basis points cuts in 2026) are expected to revive biotech financing, enhancing demand for CXO services [3][4]. - The **Chinese CXO competitive advantage** is strengthening due to economies of scale, AI-driven efficiencies, and advancements in niche technologies like antibody drug conjugates (ADCs) and peptides [3][4]. - The report forecasts **11-39% net profit growth** for major players in the CXO industry by 2026, supported by low-teen order growth [4][5]. Valuation and Investment Recommendations - Current valuations are considered attractive, with an average **30x 2026e PE** and **1.1x 2026e PEG** [4]. - Investment themes include: 1. Launch of the **1260H list** in January 2026 for risk mitigation. 2. Full-industry-chain leaders like **Wuxi Apptec** and **Wuxi Biologics** with global scalability. 3. High-growth specialists like **Wuxi XDC** focusing on niche markets and overseas expansion. 4. Domestic recovery names like **Pharmaron** offering stable profitability [5][9]. Company-Specific Updates Wuxi Apptec - Target price maintained at **RMB137.00** for A-shares and **HKD133.90** for H-shares, implying **51.2% and 30.9% upside** respectively [6][33]. Wuxi Biologics - Target price remains at **HKD45.00**, with a **37.5% upside** from current levels. Revenue estimates for 2025-27 have been slightly decreased by 1-3% due to competitive pricing pressures [20][22][33]. Wuxi XDC - Target price increased to **HKD90.50** from **HKD90.00**, reflecting a **33.2% upside**. Revenue estimates for 2025-27 have been reduced by approximately 3% each due to lower-than-expected capacity ramp-up [26][28][33]. Pharmaron - Target price set at **RMB41.00** for A-shares and **HKD30.80** for H-shares, indicating **41% and 44% upside** respectively. The valuation is based on a DCF model with unchanged assumptions [33]. Risks to Monitor - Potential expansion of US biotech restrictions and geopolitical tensions could impact the sector [4][5]. - Risks include capacity surplus from rapid industry expansion, slower-than-expected recovery in biotech financing, and increased regulatory compliance costs [4][5][25][33]. Additional Important Insights - The report emphasizes the importance of monitoring the **1260H list** updates and the potential impact of US tariffs on the CXO sector [10][25]. - The **global healthcare funding** has shown signs of recovery, with a **18% year-on-year growth** in 1H25, which may take time to reflect in CXO backlogs [12][22]. This comprehensive analysis provides a detailed overview of the current state and future outlook of the China CXO sector, highlighting key players, investment opportunities, and associated risks.

《生物安全法案》复盘 --如何看待地缘政治对中国CXO企业的影响？ 行业研究 · 行业专题 医药生物 · 医疗研发外包 投资评级：优于大市（维持评级） 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 请务必阅读正文之后的免责声明及其项下所有内容 1 报告摘要 证券研究报告 | 2025年12月28日 n 靴子落地，美国《2026财年国防授权法案》夹带《生物安全法案》生效。 请务必阅读正文之后的免责声明及其项下所有内容 2 ü 《2026财年国防授权法案》夹带《生物安全法案》（主要指第851节《禁止与特定生物技术公司签订合同》）落地，标志着美国已将生物安全正式纳入国家防务与 安全战略框架统筹考量，同时彰显其在生物技术供应链自主可控的明确政策转向，本质是中美的科技竞争与产业安全博弈在生物领域的延 ...

Investment Rating - The report maintains an "Outperform" rating for the industry [7] Core Insights - The year 2026 is expected to be a significant year for IO combined with ADC, with China leading the development of second-generation IO combined ADC therapies [5][24] - The immune therapy and ADC have a natural complementarity, enhancing efficacy and expanding the beneficiary population [17] - The report highlights the importance of innovative drugs, medical devices, and the focus on domestic demand in the pharmaceutical sector [5][48] Summary by Sections 1. IO+ADC: 2026 Catalyst Year - PD-1 combined with ADC has shown promising results in first-line NSCLC, with a global phase III trial expected to report results in 2026 [1.1][27] - Second-generation IO combined with ADC is progressing, with several global phase III studies initiated [1.2][39] 2. Weekly Market Review and Hotspot Tracking (Dec 22-26, 2025) - The CITIC Pharmaceutical Index fell by 0.2%, underperforming the CSI 300 Index by 2.1 percentage points [4][48] - The report notes a general decline in the pharmaceutical sector, with specific stocks like Hongyuan Pharmaceutical and Luyuan Pharmaceutical showing significant gains [4][63] 3. Investment Focus - The report suggests focusing on innovative drugs with commercial capabilities, potential blockbuster candidates, and cutting-edge technologies such as gene therapy and CAR-T [5][48] - Medical devices are highlighted as a sector with growth potential, particularly in areas like endoscopy and robotics [5][48]

Group 1 - JD announced that 92% of its employees will receive year-end bonuses, with total investment in bonuses increasing by over 70% year-on-year for 2025, marking the largest increase in the industry this year [2][3] - JD's retail group and functional systems will implement a two-year plan to achieve a 20-salary structure, with some departments already achieving a 19-salary structure this year [3][4] - ByteDance has also increased its bonus investment by 35% and salary adjustment investment by 1.5 times for 2025, aiming to attract and retain top talent [4][5] Group 2 - Ningde Times announced a salary adjustment for its first to sixth-level employees, increasing basic wages by 150 yuan starting January 1, 2026, along with a Spring Festival bonus plan [6][9] - In Q3 2025, Ningde Times reported revenue of 1,041.85 billion yuan, a year-on-year increase of 12.90%, and a net profit of 185.49 billion yuan, up 41.21% [7] - BYD is also implementing salary increases for its technical research and development personnel, with adjustments ranging from 500 yuan to 4,500 yuan [9] Group 3 - The central economic work conference emphasized the implementation of a plan to increase urban and rural residents' income, indicating a shift towards concrete actions to boost income across all demographics [10][12] - Since 2025, over 20 provinces have raised their minimum wage standards, with Shanghai leading at 2,740 yuan [11] - Major companies like JD, ByteDance, Ningde Times, and BYD are setting a precedent for salary increases, which is expected to enhance consumer spending power and stimulate domestic demand [12]